中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共4条，第1-4条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Wang, Zuo-wei;  Zou, Feng-ming;  Wang, Ao-li;  Yang, Jing;  Jin, Rui;  Wang, Bei-lei;  Shen, Li-juan;  Qi, Shuang;  Liu, Juan;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：45/0  |  提交时间：2022/12/22
AZD4547  RIPK1  inhibitors  SIRS model  anti-necroptosis  
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang;  Li, Xi-xiang;  Wang, Bei-lei;  Ge, Juan;  Zou, Feng-ming;  Chen, Cheng;  Wang, Jun-jie;  Hu, Chen;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：93/0  |  提交时间：2022/03/28
HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance  
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia 期刊论文
EXPERIMENTAL CELL RESEARCH, 2020, 卷号: 393
作者:  Chen, Cheng;  Wang, Li;  Li, Lili;  Wang, Aoli;  Huang, Tao;  Hu, Jie;  Zhao, Ming;  Liu, Feiyang;  Qi, Shuang;  Hu, Chen;  Wang, Wenliang;  Liu, Jing;  Ge, Jian;  Xia, Ruixiang;  Wang, Wenchao;  Liu, Qingsong
收藏  |  浏览/下载：38/0  |  提交时间：2020/11/26
Acute myeloid leukemia (AML)  Drug response  Gene mutations  
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Chen, Cheng;  Cheng, Chuan-dong;  Wu, Hong;  Wang, Zuo-wei;  Wang, Li;  Jiang, Zong-ru;  Wang, Ao-li;  Hu, Chen;  Dong, Yong-fei;  Niu, Wan-xiang;  Qi, Shuang;  Qi, Zi-ping;  Liu, Jing;  Wang, Wen-chao;  Niu, Chao-shi;  Liu, Qing-song
浏览  |  Adobe PDF(3476Kb)  |  收藏  |  浏览/下载：95/35  |  提交时间：2020/11/26
glioblastoma  osimertinib  temozolamide  MAPK-signaling pathway  MNK  eukaryotic translation initiation factor 4E